clinical trial · NCT06258525
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal CancerLiver MetastasesLiver Metastasis Colon CancerLiver InjurySinusoidal Obstruction Syndrome5-Fluorouracil ToxicityLiver Toxicity, Chemically-InducedStandard of care oxaliplatin-based chemotherapyS-adenosylmethionine (SAMe) supplementSurgery
brief summary
This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.
started
Mar 1, 2026
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Mar 18, 2026
official title
A Phase II, Open-Label Trial of S-Adenosylmethionine (SAMe) in Prevention of Oxaliplatin Associated Liver Injury
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol